查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553540

美國複合藥房市場規模、佔有率和趨勢分析報告：按類型、治療領域、年齡層、複合類型、無菌性別、細分市場預測，2024-2030

U.S. Compounding Pharmacies Market Size, Share, & Trends Analysis Report By Type (503A, 503B), By Therapeutic Area, By Age Cohort, Compounding Type, By Sterility, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國複合藥局市場成長與趨勢：

根據Grand View Research, Inc.最新報告顯示，到2030年，美國複方藥品市場規模預計將達71.8億美元，並預計2024年至2030年複合年成長率為4.89%。

由於對組合藥物的認知和採用的提高，預計該市場將顯著成長。需求增加的原因是處方量增加、藥品短缺頻繁、關鍵藥品停產。這些短缺，再加上供應鏈中斷和因 COVID-19 大流行而加劇的製造延遲問題，增加了複方藥房的關鍵作用。

FDA 表示，由於生產限制、原料短缺和物流延誤，疫情期間藥品短缺加劇。因此，複方藥局有更多的機會來填補這些藥品短缺。 FDA 甚至發布了臨時指南，允許聯邦和州許可的藥房在突發公共衛生事件期間為住院患者配製某些藥物。需求成長和監管支持的結合預計將推動市場擴張。

美國複合製藥市場報告亮點：

  • 按類型分類，503A 細分市場在 2023 年佔據最大收益佔有率。這是由於對個別患者需求的個人化藥物的需求不斷增加。
  • 按治療領域分類，疼痛管理細分市場由於其專門的方法來減輕標準疼痛管理藥物的副作用，因此在 2023 年佔據最大的市場佔有率。
  • 按年齡層分類，成人市場在 2023 年佔據最大收益佔有率。這是由於過敏、特定劑量要求以及對其他形式藥物的偏好等因素所造成的。
  • 以複方類型分類，由於有特殊需求的患者對定製藥物的需求量很大，藥物成分改變（PIA）領域在 2023 年將主導美國複方藥房市場。
  • 以無菌為基礎，由於老年和小兒科患者對靜脈注射無菌方案的巨大需求，無菌細分市場在 2023 年佔據了最大的銷售佔有率，佔據了市場主導地位。
  • 例如，2023年2月，美國著名眼科保健製藥公司Harrow Health, Inc.推出了正在申請專利的下一代組合阿托品配方。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢及展望
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTEL分析

第4章按類型分類的業務分析

  • 按類型細分儀表板
  • 美國複合藥品市場：按類型波動分析
  • 2018-2030 年美國複合製藥市場規模及趨勢分析（按類型）
  • 503A
    • 503A市場，2018-2030
  • 503B
    • 503B市場，2018-2030

第5章 治療領域業務分析

  • 按治療領域細分儀表板
  • 美國複合藥局市場：治療面積波動分析
  • 2018-2030 年美國複方製藥市場規模及趨勢分析（依治療領域）
  • 疼痛管理
    • 疼痛管理市場，2018-2030
  • 荷爾蒙補充療法
    • 荷爾蒙補充療法市場，2018-2030
  • 特種藥品
    • 特種藥品市場，2018-2030
  • 皮膚科
    • 皮膚科市場，2018-2030
  • 食品補充品
    • 營養食品市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第 6 章按年齡層別分類的業務分析

  • 按年齡層別細分儀表板
  • 美國複合藥局市場：依年齡族群變化分析
  • 2018-2030 年美國複方藥品市場規模與趨勢分析（依年齡層）
  • 兒科的
    • 兒科市場，2018-2030
  • 成人
    • 成人市場，2018-2030
  • 老年人
    • 老年人市場，2018-2030

第 7 章複利業務分析

  • 透過複合細分儀表板
  • 美國複合藥品市場：按複合類型的波動分析
  • 2018-2030年美國複方製藥市場規模及趨勢分析（依複方類型）
  • 藥物成分變化（PIA）
    • 藥物成分變更 (PIA) 市場，2018-2030
  • 目前無法使用的藥品製造 (CUPM)
    • 目前無法使用的藥品製造 (CUPM) 市場，2018-2030 年
  • 藥物劑量變更 (PDA)
    • 藥物劑量改變 (PDA) 市場，2018-2030

第8章 不孕性業務分析

  • 無菌性別細分儀表板
  • 美國複合藥局市場：無菌性別差異分析
  • 美國複合製藥市場規模及趨勢分析，不孕性別，2018-2030
  • 無菌的
    • 滅菌市場，2018-2030
  • 非無菌
    • 非無菌市場，2018-2030

第9章 競爭格局

  • 公司分類
  • 公司市場分析
  • 策略規劃
  • 公司簡介/上市公司
    • Avella Specialty Pharmacy
    • Central Admixture Pharmacy Services, Inc.
    • Clinigen Limited
    • Fagron
    • Fresenius Kabi USA
    • ImprimisRx（Harrow Health, Inc.）
    • PenCol Pharmacy
    • Sixth Avenue Medical Pharmacy
    • Triangle Compounding
    • Vertisis Custom Pharmacy
Product Code: GVR-4-68040-422-9

U.S. Compounding Pharmacies Market Growth & Trends:

The U.S. compounding pharmacies market size is anticipated to reach USD 7.18 billion by 2030 and is anticipated to grow at a CAGR of 4.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is poised for substantial growth, driven by rising awareness and adoption of compounded medications. The growing demand stems from increasing prescription volumes, frequent drug shortages, and manufacturer discontinuations of key medications. These shortages, impaired by supply chain disruptions and manufacturing delays issues that were intensified by the COVID-19 pandemic have increased the critical role of compounding pharmacies.

According to the FDA, drug shortages increased due to manufacturing restrictions, raw material shortages, and logistic delays during the pandemic. As a result, compounding pharmacies gained more opportunities to fill these gaps in drug availability. The FDA even issued temporary guidance allowing federally and state-licensed pharmacies to compound certain medications for hospitalized patients during public health emergencies. This combination of rising demand and regulatory support is expected to drive market expansion.

U.S. Compounding Pharmacies Market Report Highlights:

  • Based on type, the 503A segment held the largest revenue share in 2023. This is attributed to the rising demand for personalized medications tailored to individual patient needs.
  • Based on therapeutic area, the pain management segment dominated the market with the largest market share in 2023 due to its specialized approaches in alleviating the side effects of standard pain management medications.
  • Based on age cohort, the adult segment dominated the market with the largest revenue share in 2023 due to factors such as allergies, specific dosage requirements, and preferences for other forms of medication.
  • Based on compounding type, the pharmaceutical ingredient alteration (PIA) segment dominated the U.S. compounding pharmacies market in 2023 due to the high demand for customized drugs from patients with special needs.
  • Based on sterility, the sterile segment dominated the market with the largest revenue share in 2023 due to the significant demand for intravenous sterile planning required by geriatric and pediatric patients.
  • For instance, in February 2023, Harrow Health, Inc., a prominent U.S. eyecare pharmaceutical company, launched its patent-pending, next-generation compounded Atropine formulations, now accessible through its compounding and mail-order pharmacy subsidiary, ImprimisRx.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type
    • 1.2.2. Therapeutic Area
    • 1.2.3. Age Cohort
    • 1.2.4. Compounding Type
    • 1.2.5. Sterility
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources & Third-Party Perspectives
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing demand for personalized medications
      • 3.2.1.2. Growing importance of pharmaceutical compounding in promoting medication adherence
      • 3.2.1.3. Increasing supportive government policies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality and safety concerns
      • 3.2.2.2. Chances of human errors or medication errors
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. Compounding Pharmacies Market: Type Movement Analysis
  • 4.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
  • 4.4. 503A
    • 4.4.1. 503A Market, 2018 - 2030 (USD Million)
  • 4.5. 503B
    • 4.5.1. 503B Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Segment Dashboard
  • 5.2. U.S. Compounding Pharmacies Market: Therapeutic Area Movement Analysis
  • 5.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
  • 5.4. Pain Management
    • 5.4.1. Pain Management Market, 2018 - 2030 (USD Million)
  • 5.5. Hormone Replacement Therapy
    • 5.5.1. Hormone Replacement Therapy Market, 2018 - 2030 (USD Million)
  • 5.6. Specialty Drugs
    • 5.6.1. Specialty Drugs Market, 2018 - 2030 (USD Million)
  • 5.7. Dermatology
    • 5.7.1. Dermatology Market, 2018 - 2030 (USD Million)
  • 5.8. Nutritional Supplements
    • 5.8.1. Nutritional Supplements Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Age Cohort Business Analysis

  • 6.1. Age Cohort Segment Dashboard
  • 6.2. U.S. Compounding Pharmacies Market: Age Cohort Movement Analysis
  • 6.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Age Cohort, 2018 - 2030 (USD Million)
  • 6.4. Pediatric
    • 6.4.1. Pediatric Market, 2018 - 2030 (USD Million)
  • 6.5. Adult
    • 6.5.1. Adult Market, 2018 - 2030 (USD Million)
  • 6.6. Geriatric
    • 6.6.1. Geriatric Market, 2018 - 2030 (USD Million)

Chapter 7. Compounding Type Business Analysis

  • 7.1. Compounding Type Segment Dashboard
  • 7.2. U.S. Compounding Pharmacies Market: Compounding Type Movement Analysis
  • 7.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Compounding Type, 2018 - 2030 (USD Million)
  • 7.4. Pharmaceutical Ingredient Alteration (PIA)
    • 7.4.1. Pharmaceutical Ingredient Alteration (PIA) Market, 2018 - 2030 (USD Million)
  • 7.5. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
    • 7.5.1. Currently Unavailable Pharmaceutical Manufacturing (CUPM) Market, 2018 - 2030 (USD Million)
  • 7.6. Pharmaceutical Dosage Alteration (PDA)
    • 7.6.1. Pharmaceutical Dosage Alteration (PDA) Market, 2018 - 2030 (USD Million)

Chapter 8. Sterility Business Analysis

  • 8.1. Sterility Segment Dashboard
  • 8.2. U.S. Compounding Pharmacies Market: Sterility Movement Analysis
  • 8.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Sterility, 2018 - 2030 (USD Million)
  • 8.4. Sterile
    • 8.4.1. Sterile Market, 2018 - 2030 (USD Million)
  • 8.5. Non Sterile
    • 8.5.1. Non Sterile Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis
  • 9.3. Strategy Mapping
  • 9.4. Company Profiles/Listing
    • 9.4.1. Avella Specialty Pharmacy
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Service Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Central Admixture Pharmacy Services, Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Service Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Clinigen Limited
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Service Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Fagron
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Service Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Fresenius Kabi USA
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Service Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. ImprimisRx (Harrow Health, Inc.)
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Service Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. PenCol Pharmacy
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Service Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Sixth Avenue Medical Pharmacy
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Service Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Triangle Compounding
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Service Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Vertisis Custom Pharmacy
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Service Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. compounding pharmacies market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. compounding pharmacies market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 5 U.S. compounding pharmacies market, by age cohort, 2018 - 2030 (USD Million)
  • Table 6 U.S. compounding pharmacies market, by compounding type, 2018 - 2030 (USD Million)
  • Table 7 U.S. compounding pharmacies market, by sterility, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Model details
  • Fig. 8 U.S. Compounding Pharmacies market segmentation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Market dynamics
  • Fig. 13 Market driver relevance analysis (current & future impact)
  • Fig. 14 Market restraint relevance analysis (current & future impact)
  • Fig. 15 PESTLE analysis
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 U.S. compounding pharmacies market: Type outlook and key takeaways
  • Fig. 18 U.S. compounding pharmacies market: Type movement analysis
  • Fig. 19 503A market revenue, 2018 - 2030 (USD Million)
  • Fig. 20 503B market revenue, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. compounding pharmacies market: Therapeutic area outlook and key takeaways
  • Fig. 22 U.S. compounding pharmacies market: Therapeutic area movement analysis
  • Fig. 23 Hormone replacement therapy market revenue, 2018 - 2030 (USD Million)
  • Fig. 24 Pain management market revenue, 2018 - 2030 (USD Million)
  • Fig. 25 Specialty drugs market revenue, 2018 - 2030 (USD Million)
  • Fig. 26 Dermatology market revenue, 2018 - 2030 (USD Million)
  • Fig. 27 Nutritional supplements market revenue, 2018 - 2030 (USD Million)
  • Fig. 28 Others market revenue, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. compounding pharmacies market: Age cohort outlook and key takeaways
  • Fig. 30 U.S. compounding pharmacies market: Age cohort movement analysis
  • Fig. 31 Pediatric market revenue, 2018 - 2030 (USD Million)
  • Fig. 32 Adult market revenue, 2018 - 2030 (USD Million)
  • Fig. 33 Geriatric market revenue, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. compounding pharmacies market: Compounding type outlook and key takeaways
  • Fig. 35 U.S. compounding pharmacies market: Compounding type movement analysis
  • Fig. 36 Pharmaceutical Ingredient Alteration (PIA) market revenue, 2018 - 2030 (USD Million)
  • Fig. 37 Currently Unavailable Pharmaceutical Manufacturing (CUPM) market revenue, 2018 - 2030 (USD Million)
  • Fig. 38 Pharmaceutical Dosage Alteration (PDA) market revenue, 2018 - 2030 (USD Million)
  • Fig. 39 Others market revenue, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. compounding pharmacies market: Sterility outlook and key takeaways
  • Fig. 41 U.S. compounding pharmacies market: Sterility movement analysis
  • Fig. 42 Sterile market revenue, 2018 - 2030 (USD Million)
  • Fig. 43 Non sterile market revenue, 2018 - 2030 (USD Million)
  • Fig. 44 Company categorization
  • Fig. 45 Company market position analysis
  • Fig. 46 Strategy mapping